On Tuesday, Johnson & Johnson (NYSE:JNJ) reported a third-quarter adjusted EPS of $2.42, down 9.0% year-over-year, beating ...

Here are eight key developments from spine and orthopedic devicemakers since Oct. 9. 1. Johnson & Johnson MedTech began the ...

Johnson & Johnson’s medtech acquisitions over the past year have fueled growth for its cardiovascular group, offsetting challenges in businesses like orthopedics and surgery.

Johnson & Johnson (NYSE:JNJ) lowered its full-year earnings outlook on Tuesday despite posting better-than-expected ...

Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on third-quarter financial results and a surgical ...

JNJ's 3Q earnings expected to be $2.21 EPS and $22.16B revenue. Recent acquisitions and drug trials impacting stock's ...

Matt Miksic, an analyst from Barclays, maintained the Hold rating on Johnson & Johnson (JNJ – Research Report). The associated price ...

Johnson & Johnson's Q3 results exceeded expectations, with 26.5% year-over-year growth in the cardiovascular market and a 5.4 ...

Despite a robust increase in sales, Johnson & Johnson (JNJ) faces earnings pressure due to litigation and market headwinds.

Johnson & Johnson raised its 2024 profit and sales forecasts following strong sales of its oncology drugs. The healthcare ...

Johnson & Johnson (NYSE:JNJ) is scheduled to announce Q3 earnings results on Tuesday, October 15th, before market open.

The innovative medicine and medtech segments showed solid sales growth. Johnson & Johnson reported a strong increase in sales, but earnings fell due to one-time charges. In the wake of last year's ...